A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2019.
- 05 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2019.
- 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.